Major findings on vaccine benefits
Older adults who received the Shingrix shingles vaccine had a 24% lower risk of being diagnosed with dementia over a four-year period compared to those who were not vaccinated, according to a new study published in the Annals of Internal Medicine. Researchers at Brown University analyzed data from elderly nursing home residents who received at least one of the two required doses of Shingrix, the only shingles vaccine available in the United States.
Mechanism and implications
The study adds to a decade of research showing a connection between viral infection and cognitive decline. The shingles virus, which causes a painful rash that can persist for months, is caused by the reactivation of the chickenpox virus. Scientists believe that preventing viral reactivation may reduce chronic inflammation that contributes to dementia. Dr. Emily Darling, who led the study, noted: "This study looks at the newest vaccine in an older, vulnerable adult population at a very clear clinical point in care."
Public health potential
If confirmed by further research, the findings could position the shingles vaccine as a simple, cost-effective tool for reducing dementia risk in millions of older adults. The study specifically examined patients after a stay in skilled nursing facilities, making the results directly applicable to some of the most vulnerable elderly populations. Previous research in Britain had shown similar protective effects, and the US findings reinforce the growing consensus that vaccination may protect brain health alongside its primary function of preventing shingles.